Evaluate the relative efficiency of a targeted clinical trial design to an untargeted design under the issue of cost

DOI10.1080/03610926.2017.1295080MaRDI QIDQ4606473zbMATH OpenOpenAlexFDO

Authors Feng-shou Ko

Publication date 7 March 2018

Published in Communications in Statistics: Theory and Methods (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/03610926.2017.1295080

zbMATH Keywords

clinical trialsheterogeneitysample size determinationefficacyscreen tooltargeted design

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Discussion on the issue of sample size determination for a targeted to an untargeted and to a mixed effect model-based clinical trial design
• Designing precision medicine trials to yield a greater population impact
• Optimal treatment allocation and study duration for trials with discrete-time survival endpoints
• Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
• Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies

Cited in

(1)

• An approach to use of an adaptive procedure to clinical trials for molecularly heterogenous subject selection at interim

This page was built for publication: Evaluate the relative efficiency of a targeted clinical trial design to an untargeted design under the issue of cost

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4606473)